{"id":61157,"date":"2026-03-24T20:03:37","date_gmt":"2026-03-24T12:03:37","guid":{"rendered":"https:\/\/flcube.com\/?p=61157"},"modified":"2026-03-24T20:03:39","modified_gmt":"2026-03-24T12:03:39","slug":"gilead-to-acquire-ouro-medicines-for-2-175-billion-keymed-biosciences-secures-320-million-from-cm336-tce-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61157","title":{"rendered":"Gilead to Acquire Ouro Medicines for $2.175 Billion \u2013 Keymed Biosciences Secures $320 Million from CM336 TCE Deal"},"content":{"rendered":"\n

Keymed Biosciences Inc.<\/strong> (HKG: 2162<\/a>) announced that its NewCo partner Ouro Medicines<\/strong> has entered into a definitive merger agreement<\/strong> with Gilead Sciences (NASDAQ: GILD<\/a>)<\/strong>. Gilead will acquire Ouro Medicines for up to $2.175 billion<\/strong> ($1.675 billion upfront + $500 million milestones), with Keymed set to receive approximately $320 million<\/strong> ($250 million upfront + $70 million milestones) as a shareholder. The transaction accelerates global development of CM336\/OM336<\/strong>, a potential best-in-class T-cell engager (TCE)<\/strong> for autoimmune diseases, with tiered royalties now fulfilled by Gilead<\/strong>.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Gilead Sciences (NASDAQ: GILD)<\/td><\/tr>
Target<\/strong><\/td>Ouro Medicines (NewCo established November 2024)<\/td><\/tr>
Total Deal Value<\/strong><\/td>Up to $2.175 billion<\/strong> ($1.675B upfront + $500M milestones)<\/td><\/tr>
Keymed Stake<\/strong><\/td>Shareholder of Ouro Medicines<\/td><\/tr>
Keymed Proceeds<\/strong><\/td>~$250 million upfront + ~$70 million milestones = ~$320 million total<\/strong><\/td><\/tr>
Post-Deal Equity<\/strong><\/td>Keymed no longer holds equity<\/strong> in Ouro Medicines<\/td><\/tr>
Royalty Structure<\/strong><\/td>Tiered royalties for CM336\/OM336 now paid by Gilead<\/strong> (vs. Ouro Medicines previously)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

CM336\/OM336 Asset Profile<\/h2>\n\n\n\n
Attribute<\/th>CM336\/OM336 Specification<\/th><\/tr><\/thead>
Format<\/strong><\/td>T-cell engager (TCE)<\/strong> \u2013 bispecific antibody architecture<\/td><\/tr>
Target<\/strong><\/td>CD3 + B-cell target (specific target undisclosed)<\/td><\/tr>
Development Focus<\/strong><\/td>Autoimmune diseases<\/strong> with significant unmet clinical needs<\/td><\/tr>
Positioning<\/strong><\/td>Potential best-in-class TCE<\/strong> for B-cell mediated autoimmunity<\/td><\/tr>
Global Rights<\/strong><\/td>Ouro Medicines (now Gilead)<\/strong> \u2013 worldwide ex-Greater China<\/td><\/tr>
China Rights<\/strong><\/td>Retained by Keymed Biosciences<\/strong> (per original November 2024 agreement)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Timeline & Partnership History<\/h2>\n\n\n\n
Date<\/th>Milestone<\/th><\/tr><\/thead>
November 2024<\/strong><\/td>Keymed grants Ouro Medicines exclusive global rights<\/strong> (ex-Greater China) to CM336\/OM336 for development, manufacturing, registration, commercialization<\/td><\/tr>
March 2026<\/strong><\/td>Gilead acquires Ouro Medicines; Keymed receives $320 million<\/strong>; royalties transferred to Gilead<\/td><\/tr>
Post-Acquisition<\/strong><\/td>Accelerated global development<\/strong> of CM336\/OM336 as autoimmune TCE; Gilead immunology franchise expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Impact & Value Creation<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Keymed Value Realization<\/strong><\/td>$320 million cash infusion<\/strong> (vs. ~$180 million market cap pre-announcement) \u2013 transformational liquidity event for China biotech<\/td><\/tr>
Gilead Immunology Strategy<\/strong><\/td>Acquires clinical-stage TCE platform<\/strong> to complement filgotinib (JAK) and expand into B-cell depletion autoimmunity<\/strong> (SLE, MS, myasthenia gravis)<\/td><\/tr>
CM336\/OM336 Acceleration<\/strong><\/td>Gilead’s global development infrastructure<\/strong> and regulatory expertise<\/strong> fast-tracks Phase II\/III vs. NewCo standalone financing<\/td><\/tr>
Keymed China Retained Rights<\/strong><\/td>Domestic TCE franchise<\/strong> preserved; potential for China-first approval<\/strong> and subsequent ex-China royalty stream from Gilead<\/strong><\/td><\/tr>
NewCo Model Validation<\/strong><\/td>Demonstrates asset monetization pathway<\/strong> for China biotechs: license to NewCo \u2192 Big Pharma acquisition \u2192 cash + royalty returns to originator<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n